Cingulate Inc. Files 8-K: Board and Compensation Changes
Ticker: CINGW · Form: 8-K · Filed: Jan 24, 2025 · CIK: 1862150
| Field | Detail |
|---|---|
| Company | Cingulate Inc. (CINGW) |
| Form Type | 8-K |
| Filed Date | Jan 24, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $165,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-changes, executive-compensation, filing
Related Tickers: CING
TL;DR
Cingulate Inc. filed an 8-K on Jan 17, 2025, reporting board and exec comp changes.
AI Summary
On January 17, 2025, Cingulate Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indicates a shift in leadership and potential adjustments to how key personnel are compensated.
Why It Matters
Changes in board composition and executive compensation can signal strategic shifts or financial adjustments within the company, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty regarding the company's strategic direction and financial stability.
Key Players & Entities
- Cingulate Inc. (company) — Registrant
- January 17, 2025 (date) — Date of earliest event reported
FAQ
What specific changes were made to the board of directors?
The filing indicates changes related to the 'Departure of Directors or Certain Officers' and 'Election of Directors', but specific names and details of the changes are not provided in the excerpt.
What are the details of the new compensatory arrangements for certain officers?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item of disclosure, but the specific details of these arrangements are not included in the provided text.
What is the primary business of Cingulate Inc.?
Cingulate Inc. is in the 'PHARMACEUTICAL PREPARATIONS' industry, with SIC code 2834.
When was this 8-K filing submitted?
The filing was submitted on January 24, 2025, with the earliest event reported on January 17, 2025.
What is Cingulate Inc.'s principal executive office address?
The principal executive offices are located at 1901 W. 47th Place, Kansas City, KS 66205.
Filing Stats: 571 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2025-01-24 17:00:31
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share CING The Nasdaq Stock Mar
- $165,000 — led to receive an annual base salary of $165,000 and will no longer be entitled to recei
Filing Documents
- form8-k.htm (8-K) — 46KB
- ex10-1.htm (EX-10.1) — 15KB
- 0001493152-25-003619.txt ( ) — 283KB
- cing-20250117.xsd (EX-101.SCH) — 4KB
- cing-20250117_def.xml (EX-101.DEF) — 29KB
- cing-20250117_lab.xml (EX-101.LAB) — 36KB
- cing-20250117_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
02
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers On January 17, 2025, the Compensation Committee of the Board of Directors of Cingulate Inc. (the "Company") approved an amendment, effective January 1, 2025 (the "Amendment"), to the Employment Agreement between Matthew N. Brams, Executive Vice President and Chief Medical Officer, and Cingulate Therapeutics LLC , effective September 23, 2021, as amended. Pursuant to the Amendment, Mr. Brams will be entitled to receive an annual base salary of $165,000 and will no longer be entitled to receive quarterly equity grants. Mr. Brams will continue to be entitled to receive an annual equity grant as determined by the Compensation Committee. The foregoing description of the Amendment is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein. Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1 Amendment to Employment Agreement, effective January 1, 2025, between Cingulate Therapeutics, LLC and Matthew N. Brams 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CINGULATE INC. Dated: January 24, 2025 By: /s/ Shane J. Schaffer Name: Shane J. Schaffer Title: Chief Executive Officer